Oncology

  • Pulmonary nodule management—patients first, guidelines second

    Louis S. H. Lam, MD
    • Cleveland Clinic Journal of Medicine August 2026, 93 (8) 485-486;
    • DOI: https://doi.org/10.3949/ccjm.93a.26060
    • How we communicate nodule findings to our patients can influence their perception and whether they agree with and adhere to recommendations.

  • Navigating pulmonary nodules: Guidelines on assessing risk and determining next steps in primary care

    CME Image
    Noah Gordon, DO, Raisa Munshi, MD, Mae Leef, DO, Axel W. Joob, MD and Abdul Hamid Alraiyes, MD
    • Cleveland Clinic Journal of Medicine August 2026, 93 (8) 475-484;
    • DOI: https://doi.org/10.3949/ccjm.93a.26004
    • The authors offer practical guidance on identifying pulmonary nodules that require surveillance, determining appropriate follow-up intervals, and deciding when specialist evaluation and intervention are needed.

  • TOC Icon

    Winning the battle against Barrett esophagus and esophageal adenocarcinoma

    David A. Katzka, MD
    • Cleveland Clinic Journal of Medicine August 2026, 93 (8) 467-473;
    • DOI: https://doi.org/10.3949/ccjm.93gr.26054
    • Current efforts are focused on better identifying patients at high risk for Barrett esophagus as candidates for endoscopic screening and developing less invasive and cheaper detection methods.

  • Barriers to cancer screening in transgender women

    Maryam Sattari, MD, MS
    • Cleveland Clinic Journal of Medicine December 2025, 92 (12) 721;
    • DOI: https://doi.org/10.3949/ccjm.92c.12001
  • Breast cancer risk and screening for transgender and gender-diverse individuals

    Dzhuliyan V. Vasilev, MD, MMSc, Juliana M. Kling, MD, MPH and Evelyn F. Carroll, MD
    • Cleveland Clinic Journal of Medicine July 2025, 92 (7) 439-447;
    • DOI: https://doi.org/10.3949/ccjm.92a.24088
    • Evidence on breast cancer risk in transgender and gender-diverse individuals is limited, and recent guidelines are primarily based on expert consensus, retrospective cohort studies, and extrapolation from cisgender populations.

  • How should I manage my patient with cancer who is experiencing diarrhea while on immunotherapy?

    Rupayan Kundu, MD, Arjun Chatterjee, MD, Jessica Philpott, MD, PhD and Lucy Boyce Kennedy, MD
    • Cleveland Clinic Journal of Medicine July 2025, 92 (7) 401-405;
    • DOI: https://doi.org/10.3949/ccjm.92a.24090
    • Diarrhea and colitis, which can result from infection or be complications of immune checkpoint inhibitors, require prompt evaluation so that appropriate treatment can be started.

  • Immunotherapy meets William Shakespeare

    Brian F. Mandell, MD, PhD
    • Cleveland Clinic Journal of Medicine July 2025, 92 (7) 390-391;
    • DOI: https://doi.org/10.3949/ccjm.92b.07025
    • Immune checkpoint inhibitors are potentially life-saving therapies that can trigger a wide range of autoimmune pathology.

  • Cervical cancer screening in high-risk patients: Clinical challenges in primary care

    Rebecca S. Gold, MD, MAS, Meagan Williams, MD and Heather M. Wainstein, MD
    • Cleveland Clinic Journal of Medicine November 2024, 91 (11) 693-703;
    • DOI: https://doi.org/10.3949/ccjm.91a.24023
    • The authors provide up-to-date guidance on cervical cancer screening, surveillance, and management for high-risk patients.

  • Hematologic complications after kidney and pancreas transplant in a patient with chronic myeloid leukemia

    Binoy Yohannan, MD, Allen Omo-Ogboi, MD, Johncy John Kachira, MBBS and Harinder Juneja, MD
    • Cleveland Clinic Journal of Medicine March 2024, 91 (3) 183-190;
    • DOI: https://doi.org/10.3949/ccjm.91a.23042
    • This case highlights the complex interplay linking autoimmunity, solid-organ transplant, myeloid neoplasm, and Evans syndrome.

  • Management of venous thromboembolism in patients with active cancer

    Heloni M. Dave, MBBS and Alok A. Khorana, MD, FACP, FASCO
    • Cleveland Clinic Journal of Medicine February 2024, 91 (2) 109-117;
    • DOI: https://doi.org/10.3949/ccjm.91a.23017
    • The authors review the presentation and diagnosis of venous thromboembolism in patients with cancer and present an approach to treatment that aims to balance the bleeding risk from anticoagulation with the risk of recurrent thrombosis.

Previous